Following the science to help people maintain and improve cardiovascular and metabolic health

An enduring, bold ambition to break through conventional thinking in cardiovascular and metabolic health

Tangent Pharma has a patient-centric approach to disease treatment, so we are tackling multiple risk factors by uniting our cardiovascular (CV), metabolic and chronic kidney disease (CKD) disease areas into one integrated approach – cardiovascular and metabolic disease (CVMD).

This approach means we look at the CVMD patient as a whole, rather than by disease area, because we know that cardiovascular disease (CVD) is a well-known consequence of diabetes and CKD. Each of our focus areas seek to further reduce cardiovascular morbidity and mortality, and organ damage by addressing multiple CV risk factors.


Tangent Pharma has been driving CV innovation since the day one. As we aim to break through conventional thinking by following what the science is telling us, we will:

- continue to build our CV and diabetes portfolio to help a broader range of patients

- focus on investigating the impact of treatment options on reducing CV events and death in a broad range of high-risk patients, beyond acute coronary syndromes (ACS)

- shift the treatment paradigm of Type 2 diabetes to early combination therapy and accelerate achievement of treatment goals

- develop new therapies for anaemia in people with CKD.

Our enduring goal is to push the boundaries of science to deliver life-changing medicines to the people who need them, and contribute to improved health for millions more people around the world.